LONNN Stock Chart & Stats
$11842.56
$0.00(0.00%)
At close: 4:00 PM EDT
$11842.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11,700.00 - $13,580.58
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$811.08B
Enterprise Value$41.89K
Total Cash (Recent Filing)$487.00M
Total Debt (Recent Filing)$4.17B
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Jan 27, 2027EPS Estimate
198.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding70,229,020
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)4.12
Price to Sales (P/S)5.77
P/FCF Ratio-184.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14,802.20Price Target Upside24.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)382.17
Revenue Forecast (FY)$149.38B
Bulls Say, Bears Say
Bulls Say
Broad-based Organic GrowthGrowth across Integrated Biologics, Advanced Synthesis and Specialized Modalities indicates broad customer demand rather than reliance on one business. This diversified platform performance can support more resilient revenue expansion over the next several quarters.
Sustainable Margin ImprovementMaterial margin expansion, improved returns and stronger operating leverage point to better execution and utilization. Although some normalization is expected, the upgraded margin outlook supports a stronger earnings base and improves the economics of future growth.
Strategic CDMO Focus And Capacity InvestmentThe completed strategic shift concentrates Lonza on outsourced development and manufacturing, where specialized capabilities can deepen customer relationships. Targeted ADC capacity and return thresholds should strengthen long-term positioning in complex, higher-value modalities.
Bears Say
Recent Revenue And Margin DeteriorationThe weaker recent financial trajectory shows that demand, mix or cost pressures have not fully resolved. Even with a strong H1 2026, the gap from prior profitability peaks creates execution risk and may limit how much of the recovery persists.
Weak Multi-year Free Cash Flow ConversionPersistent negative free cash flow indicates that capital spending and working-capital needs have absorbed operating inflows. This constrains financial flexibility and makes returns dependent on successful utilization of Lonza’s substantial investment program.
Rising Leverage And Lower Balance-sheet FlexibilityLonza remains well capitalized, but higher leverage alongside slightly lower assets and equity reduces room to absorb prolonged margin pressure. This matters because the company is pursuing large capacity investments while cash conversion remains uneven.
Lonza Group Ltd News
LONNN FAQ
What was Lonza Group Ltd’s price range in the past 12 months?
Lonza Group Ltd lowest stock price was $11700.00 and its highest was $13580.58 in the past 12 months.
What is Lonza Group Ltd’s market cap?
Lonza Group Ltd’s market cap is $811.08B.
When is Lonza Group Ltd’s upcoming earnings report date?
Lonza Group Ltd’s upcoming earnings report date is Jan 27, 2027 which is in 140 days.
How were Lonza Group Ltd’s earnings last quarter?
Lonza Group Ltd released its earnings results on Jul 22, 2026. The company reported $173.932 earnings per share for the quarter, missing the consensus estimate of $183.971 by -$10.039.
Is Lonza Group Ltd overvalued?
According to Wall Street analysts Lonza Group Ltd’s price is currently Undervalued.
Does Lonza Group Ltd pay dividends?
Lonza Group Ltd does not currently pay dividends.
What is Lonza Group Ltd’s EPS estimate?
Lonza Group Ltd’s EPS estimate is 198.19.
How many shares outstanding does Lonza Group Ltd have?
Lonza Group Ltd has 70,229,020 shares outstanding.
What happened to Lonza Group Ltd’s price movement after its last earnings report?
Lonza Group Ltd reported an EPS of $173.932 in its last earnings report, missing expectations of $183.971. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lonza Group Ltd?
Currently, no hedge funds are holding shares in MX:LONNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lonza Group Ltd
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
LONNN Stock 12 Month Forecast
Average Price Target
$14,802.20
▲(24.99% Upside)